Barbara Weber - Feb 3, 2025 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
Chief Executive Officer, Director
Signature
/s/ Douglas Barry, as attorney-in-fact
Stock symbol
TNGX
Transactions as of
Feb 3, 2025
Transactions value $
$0
Form type
4
Date filed
2/5/2025, 07:31 PM
Previous filing
Oct 10, 2024
Next filing
Feb 6, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNGX Common Stock Award $0 +106K +6.9% $0.00 1.64M Feb 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNGX Stock Option (Right to Buy) Award $0 +635K $0.00 635K Feb 3, 2025 Common Stock 635K $2.91 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 2, 2026, 33% on February 1, 2027 and 34% on February 14, 2028, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2 This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter.